Collegium bring in former Biogen SVP as new COO
Collegium Pharmaceutical has announced the appointment of Joseph Ciaffoni to the position of Executive Vice President and Chief Operating Officer. Collegium Pharma is a speciality company that is developing abuse-deterrent products for the treatment of chronic pain.
Ciaffoni begins the new role effective immediately. He brings with him a broad range of experience from different pharmaceutical companies, having worked at six different pharmaceutical companies in the preceding 15 years. He occupied the role of President of US Branded Pharmaceuticals for Endo Pharmaceuticals prior to joining Collegium and held roles at Biogen for over 4 year, performing the role of Senior Vice President of its Global Speciality Medicines Group when he left.
Speaking on his appointment, Ciaffoni explained his decision to join the company: “Opioid abuse and misuse is a significant problem across the country [US], at the same time that chronic pain patients are seeking effective treatments. I believe that Xtampza ER can be a critical part of the solution. I’m excited to join Collegium at this important point in the company’s evolution”.
“We are excited to have Joe join Collegium in this newly created role,” said Mike Heffernan, Collegium’s CEO. “Joe’s industry experience is extensive and includes building commercial businesses, leading emerging growth and multi-national organizations and achieving success across multiple therapeutic categories, including pain management. Joe has a proven track record of success across multiple product launches and the commercialisation of numerous products.”
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …